Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05908240 · ClinicalTrials.gov registry record · NA
Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis
A NA study of Cardiovascular Diseases and Psoriasis, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- NA
- Development phase
- 520
- Enrollment target
- 10
- Study locations
NCT05908240: Recruiting NA study of Cardiovascular Diseases and Psoriasis, sponsored by University of Pennsylvania.
NCT05908240 is a NA study of Cardiovascular Diseases and Psoriasis that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 520 participants, below the 26,973-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (98% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05908240, a NA study of Cardiovascular Diseases and Psoriasis, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- NA
- Development phase
- 520 participants
- Enrollment target
- 10
- Study locations
Study Summary
The goal of this research is to test a novel centralized care coordinator program to assist patients with psoriatic disease in lowering their risk of cardiovascular disease through the application of standard of care approaches to improving modifiable cardiovascular risk factors.
Primary Outcome
Change in LDL cholesterol
Conditions Studied
Interventions
- OTHER Care Coordinator Model
Study Locations (10)
Indiana
- Dawes Fretzin Clinical Research - Columbus
- Dawes Fretzin Clinical Research - Indianapolis
Pennsylvania
- City Dermatology - Bensalem
- University of Pennsylvania - Philadelphia
Arkansas
- Johnson Dermatology - Fort Smith
Michigan
- MiSkinCenter - Northville
New York
- SUNY Downstate - Brooklyn
Utah
- University of Utah - Salt Lake City
Virginia
- University of Virginia - Charlottesville
Washington
- Bellevue Dermatology Clinic - Bellevue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 520 participants |
| Start Date | 2023-06-15 |
| Est. Completion | 2026-07 |
| Phase | NA |
What NCT05908240 shows while recruiting
NCT05908240 is an interventional study that assigns participants to a tested intervention. The registered 520 participants enrollment target is mid-sized for trials with a published cap, below the 26,973-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (98% lower).
The record links to 4 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 1 intervention - of which Care Coordinator Model is the first listed.
NCT05908240 lists 10 locations in 8 states (Indiana, Pennsylvania, Arkansas).
Frequently Asked Questions
What is clinical trial NCT05908240 about?
NCT05908240 is a clinical study titled "Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis". The goal of this research is to test a novel centralized care coordinator program to assist patients with psoriatic disease in lowering their risk of cardiovascular disease through the application of standard of care approaches to improving modifiable cardiovascular risk factors.
What is the current status of trial NCT05908240?
This trial is currently recruiting. It is a NA study. The enrollment target is 520 participants. The study started on 2023-06-15. Estimated completion is 2026-07.
What conditions does trial NCT05908240 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Psoriasis, Psoriatic Arthritis, Psoriatic Conditions.
What interventions are being tested in trial NCT05908240?
The interventions under investigation include: Care Coordinator Model (OTHER).
Who is sponsoring clinical trial NCT05908240?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05908240 being conducted?
This trial has 10 study locations across Arkansas, Indiana, Michigan, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05908240's enrollment target sits among peer trials
520 91st of 300 higher than 210 of 300 other Cardiovascular Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health
RECRUITING · NA
-
Identifying Strategies to Reduce Cardiovascular Risk Among Mothers of Young Children
RECRUITING · NA
-
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323581 · 520 participants · NA
Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts
- NCT04656496 · 520 participants · NA
NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors
- NCT05445778 · 520 participants · Phase 3
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
- NCT05498428 · 520 participants · Phase 2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI